Coya Therapeutics (COYA) CEO Issues Letter to Stockholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
December 13, 2023 8:00 AM ESTHOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman.
Dear Fellow... More
